This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...

Recursion Pharmaceuticals’s stock price closed at $5.00. It is down -6.72% in the last 3 months and down -28.26% in the last 12 months. Recursion Pharmaceuticals saw 0 positive EPS revisions and 4 ...

We recently published 12 Best Healthcare Stocks to Buy Under $30. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.27, marking a +1.15% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.83%. At ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is a leader in the TechBio space "due to its broad capabilities and extensive internal data generation," according to Needham. The Recursion Pharmaceuticals ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...

Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination Bayer to become first ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...